In breast cancer, low TCL6 expression independently predicts an adverse outcome for PR (estrogen and progesterone receptor)-negative patients, while also correlating with immune infiltrating cells, including B cells, CD4+ T cells, and CD8+ T cells. This evidence concerns the gene PGR and breast carcinoma.